Griffin DE, 2007. Alphaviruses, pp 1023–1068. In Fields BN, Knipe DM, Howley PM, eds. Fields Virology, 6th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins.
Nasar F et al. 2012. Eilat virus, a unique alphavirus with host range restricted to insects by RNA replication. Proc Natl Acad Sci USA 109: 14622–14627.
Weaver SC, Lecuit M, 2015. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med 372: 1231–1239.
Anderson CR, Downs WG, Wattley GH, Ahin NW, Reese AA, 1957. Mayaro virus: a new human disease agent. II. Isolation from blood of patients in Trinidad, B.W.I. Am J Trop Med Hyg 6: 1012–1016.
Karabatsos N, 1978. Supplement to international catalogue of arboviruses including certain other viruses of vertebrates. Am J Trop Med Hyg 27: 372–440.
Tesh RB et al. 1999. Mayaro virus disease: an emerging mosquito-borne zoonosis in tropical South America. Clin Infect Dis 28: 67–73.
Lednicky J et al. 2016. Mayaro virus in child with acute febrile illness, Haiti, 2015. Emerg Infect Dis 22: 2000–2002.
Llagonne-Barets M, Icard V, Leparc-Goffart I, Prat C, Perpoint T, Andre P, Ramiere C, 2016. A case of Mayaro virus infection imported from French Guiana. J Clin Virol 77: 66–68.
Santiago FW, Halsey ES, Siles C, Vilcarromero S, Guevara C, Silvas JA, Ramal C, Ampuero JS, Aguilar PV, 2015. Long-term arthralgia after Mayaro virus infection correlates with sustained pro-inflammatory cytokine response. PLoS Negl Trop Dis 9: e0004104.
Causey OR, Casals J, Shope RE, Udomsakdi S, 1963. Aura and Una, two new group a arthropod-borne viruses. Am J Trop Med Hyg 12: 777–781.
Diaz LA, Spinsanti LI, Almiron WR, Contigiani MS, 2003. UNA virus: first report of human infection in Argentina. Rev Inst Med Trop Sao Paulo 45: 109–110.
Chang AY et al. 2018. Frequency of chronic joint pain following chikungunya virus infection: a Colombian cohort study. Arthritis Rheumatol 70: 578–584.
Chang AY et al. 2018. Chikungunya arthritis mechanisms in the Americas: a cross-sectional analysis of chikungunya arthritis patients twenty-two months after infection demonstrating no detectable viral persistence in synovial fluid. Arthritis Rheumatol 70: 585–593.
Binn LN, Harrison VR, Randall R, 1967. Patterns of viremia and antibody observed in rhesus monkeys inoculated with chikungunya and other serologically related group A arboviruses. Am J Trop Med Hyg 16: 782–785.
Casals J, Whitman L, 1957. Mayaro virus: a new human disease agent. I. Relationship to other arbor viruses. Am J Trop Med Hyg 6: 1004–1011.
Porterfield JS, 1960. A simple plaque-inhibition test for the study of arthropod-borne viruses. Bull World Health Organ 22: 373–380.
Porterfield JS, 1961. Cross-neutralization studies with group A arthropod-borne viruses. Bull World Health Organ 24: 735–741.
Partidos CD, Paykel J, Weger J, Borland EM, Powers AM, Seymour R, Weaver SC, Stinchcomb DT, Osorio JE, 2012. Cross-protective immunity against o’nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. Vaccine 30: 4638–4643.
Pittman PR, Liu CT, Cannon TL, Mangiafico JA, Gibbs PH, 2009. Immune interference after sequential alphavirus vaccine vaccinations. Vaccine 27: 4879–4882.
Pittman PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH, Peters CJ, 1996. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14: 337–343.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 470 | 351 | 21 |
Full Text Views | 709 | 21 | 0 |
PDF Downloads | 338 | 18 | 0 |
Most alphaviruses are mosquito-borne and can cause severe disease in domesticated animals and humans. The most notable recent outbreak in the Americas was the 2014 chikungunya virus (CHIKV) outbreak affecting millions and producing disease highlighted by rash and arthralgia. Chikungunya virus is a member of the Semliki Forest (SF) serocomplex, and before its arrival in the Americas, two other member of the SF complex, Una (UNAV) and Mayaro (MAYV) viruses, were circulating in Central and South America. This study examined whether antibodies from convalescent CHIKV patients could cross-neutralize UNAV and MAYV. Considerable cross-neutralization of both viruses was observed, suggesting that exposure to CHIKV can produce antibodies that may mitigate infection with UNAV or MAYV. Understanding the impact of CHIKV exposure on population susceptibility to other emerging viruses may help predict outbreaks; moreover, identification of cross-reactive immune responses among alphaviruses may lead to the development of vaccines targeting multiple viruses.
Financial support: This study was supported by a grant from the U.S. Food and Drug Administration IAA 224-15-8035S.
Disclosure: The views expressed in this article are those of the authors and do not reflect the official policy or position of the U.S. Department of Defense, or the Department of the Army.
Authors’ addresses: Karen A. Martins and Melissa K. Gregory, Division of Medicine, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD, E-mails: karen.a.martins2.civ@mail.mil, and melissa.k.gregory3.ctr@mail.mil. Stephanie M. Valdez, Thomas R. Sprague, Margaret L. Pitt, and Farooq Nasar, Virology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD, E-mails: valdezs@vt.edu, thomas.r.sprague7.ctr@mail.mil, margaret.l.pitt.civ@mail.mil, and farooq.nasar.ctr@mail.mil. Liliana Encinales and Nelly Pacheco, Allied Research Society, Barranquilla, Colombia, E-mails: liliana_encinales@yahoo.com and nepamer20@hotmail.com. Carlos Cure, Biomelab, Barranquilla, Colombia, E-mail: cacurec@gmail.com. Alexandra Porras-Ramirez and Alejandro Rico-Mendoza, Universidad el Bosque, Bogota, Colombia, E-mails: porras.alexandra@gmail.com, and aricom@unbosque.edu.co. Aileen Chang, Washington University, Washington, DC, E-mail: achang@mfa.gwu.edu.
Griffin DE, 2007. Alphaviruses, pp 1023–1068. In Fields BN, Knipe DM, Howley PM, eds. Fields Virology, 6th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins.
Nasar F et al. 2012. Eilat virus, a unique alphavirus with host range restricted to insects by RNA replication. Proc Natl Acad Sci USA 109: 14622–14627.
Weaver SC, Lecuit M, 2015. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med 372: 1231–1239.
Anderson CR, Downs WG, Wattley GH, Ahin NW, Reese AA, 1957. Mayaro virus: a new human disease agent. II. Isolation from blood of patients in Trinidad, B.W.I. Am J Trop Med Hyg 6: 1012–1016.
Karabatsos N, 1978. Supplement to international catalogue of arboviruses including certain other viruses of vertebrates. Am J Trop Med Hyg 27: 372–440.
Tesh RB et al. 1999. Mayaro virus disease: an emerging mosquito-borne zoonosis in tropical South America. Clin Infect Dis 28: 67–73.
Lednicky J et al. 2016. Mayaro virus in child with acute febrile illness, Haiti, 2015. Emerg Infect Dis 22: 2000–2002.
Llagonne-Barets M, Icard V, Leparc-Goffart I, Prat C, Perpoint T, Andre P, Ramiere C, 2016. A case of Mayaro virus infection imported from French Guiana. J Clin Virol 77: 66–68.
Santiago FW, Halsey ES, Siles C, Vilcarromero S, Guevara C, Silvas JA, Ramal C, Ampuero JS, Aguilar PV, 2015. Long-term arthralgia after Mayaro virus infection correlates with sustained pro-inflammatory cytokine response. PLoS Negl Trop Dis 9: e0004104.
Causey OR, Casals J, Shope RE, Udomsakdi S, 1963. Aura and Una, two new group a arthropod-borne viruses. Am J Trop Med Hyg 12: 777–781.
Diaz LA, Spinsanti LI, Almiron WR, Contigiani MS, 2003. UNA virus: first report of human infection in Argentina. Rev Inst Med Trop Sao Paulo 45: 109–110.
Chang AY et al. 2018. Frequency of chronic joint pain following chikungunya virus infection: a Colombian cohort study. Arthritis Rheumatol 70: 578–584.
Chang AY et al. 2018. Chikungunya arthritis mechanisms in the Americas: a cross-sectional analysis of chikungunya arthritis patients twenty-two months after infection demonstrating no detectable viral persistence in synovial fluid. Arthritis Rheumatol 70: 585–593.
Binn LN, Harrison VR, Randall R, 1967. Patterns of viremia and antibody observed in rhesus monkeys inoculated with chikungunya and other serologically related group A arboviruses. Am J Trop Med Hyg 16: 782–785.
Casals J, Whitman L, 1957. Mayaro virus: a new human disease agent. I. Relationship to other arbor viruses. Am J Trop Med Hyg 6: 1004–1011.
Porterfield JS, 1960. A simple plaque-inhibition test for the study of arthropod-borne viruses. Bull World Health Organ 22: 373–380.
Porterfield JS, 1961. Cross-neutralization studies with group A arthropod-borne viruses. Bull World Health Organ 24: 735–741.
Partidos CD, Paykel J, Weger J, Borland EM, Powers AM, Seymour R, Weaver SC, Stinchcomb DT, Osorio JE, 2012. Cross-protective immunity against o’nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. Vaccine 30: 4638–4643.
Pittman PR, Liu CT, Cannon TL, Mangiafico JA, Gibbs PH, 2009. Immune interference after sequential alphavirus vaccine vaccinations. Vaccine 27: 4879–4882.
Pittman PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH, Peters CJ, 1996. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14: 337–343.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 470 | 351 | 21 |
Full Text Views | 709 | 21 | 0 |
PDF Downloads | 338 | 18 | 0 |